Market Movers: Enanta (ENTA) Jumps 5.42% to Close at $68.09 August 4

Equities Staff  |

Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) traded 5.42% up on August 4 to close at $68.09.

285,872 traded today. Their current average 30 day volume is 202,649 shares.

Enanta lost 13.63% year-to-date in 2022.

The company expects its next earnings on 2022-08-04.

For technical charts, analysis, and more on Enanta visit the company profile.

About Enanta Pharmaceuticals Inc

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.

To get more information on Enanta Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Enanta Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content